<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697954</url>
  </required_header>
  <id_info>
    <org_study_id>5180114</org_study_id>
    <nct_id>NCT03697954</nct_id>
  </id_info>
  <brief_title>Direct Full-stage Implantation of Sacral Neuromodulation</brief_title>
  <official_title>Direct Full-stage Implantation of Sacral Neuromodulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigator-initiated study is to investigate the efficacy and costs of
      direct full stage sacral neuromodulation in patients with overactive bladder. Patients with
      refractory OAB and urge urinary incontinence will undergo direct full stage implantation and
      be followed for a period of 6 months to monitor symptom improvement with voiding diaries and
      validated questionnaires preoperatively and postoperatively. Therapeutic and adverse outcomes
      will be evaluated. The use of medical resources and time off of work will be analyzed as
      well. This will be a descriptive study with no additional arms or randomization.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in overactive bladder symptoms</measure>
    <time_frame>1 year</time_frame>
    <description>measured using overactive bladder questionnaire</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Urinary Bladder, Overactive</condition>
  <condition>Urge Incontinence</condition>
  <arm_group>
    <arm_group_label>overactive bladder patients</arm_group_label>
    <description>Female patients with refractory overactive bladder and urge urinary incontinence undergoing direct full stage implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>full stage implantation of sacral neuromodulation</intervention_name>
    <description>full stage implantation of sacral neuromodulation for overactive bladder and urge incontinence</description>
    <arm_group_label>overactive bladder patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with refractory overactive bladder and urge urinary incontinence undergoing direct
        full stage implantation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years of age

          -  Female gender

          -  Refractory overactive bladder: wet failing treatment with two or more anticholinergic
             and/or beta-3 agonist agents

          -  Willing to stop treatment with anticholingeric and/or beta-3 agonist agents during the
             study period (2 week washout period preoperatively and 6 months postoperative)

          -  Willing and able to complete study questionnaires, use Medtronic device programmer,
             return for scheduled follow-up appointments

          -  Surgical candidate able to hold antiplatelet or anticoagulation prior to surgery

          -  Health insurance provider that will cover full-stage implantation

        Exclusion Criteria:

          -  Age &lt;18

          -  Pregnant or planning to become pregnant

          -  Male gender

          -  Unable or unwilling to stop anticholingeric and/or beta-3 agonist agents during the
             study period

          -  Treatment with botulinum toxin within last 6 months

          -  Recent surgery for stress urinary incontinence or pelvic organ prolapse within last 6
             months

          -  Severe pelvic organ prolapse

          -  Post-void residual &gt;150 ml

          -  Symptomatic or recurrent urinary tract infection

          -  Neurologic disorders: cerebrovascular accident with neurologic deficits, Parkinson's,
             multiple sclerosis, spinal cord injury, significant peripheral neuropathy

          -  Cognitive disorders, e.g. dementia

          -  Interstitial cystitis or chronic pelvic pain syndrome

          -  Poorly controlled diabetes mellitus (HbA1c &gt;10%)

          -  History of bladder malignancy, pelvic radiation, urinary retention requiring
             catheterization

          -  Anticipated or known need for MRI at the trunk

          -  History of or anticipated surgery at the lower back

          -  Unable to hold antiplatelet or anticoagulation prior to surgery

          -  Life expectancy &lt;1 year
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Loma Linda University Faculty Medical Offices</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011 Oct;108(7):1132-8. doi: 10.1111/j.1464-410X.2010.09993.x. Epub 2011 Jan 13.</citation>
    <PMID>21231991</PMID>
  </reference>
  <reference>
    <citation>Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, Pashos CL. Economic costs of overactive bladder in the United States. Urology. 2010 Mar;75(3):526-32, 532.e1-18. doi: 10.1016/j.urology.2009.06.096. Epub 2009 Dec 29.</citation>
    <PMID>20035977</PMID>
  </reference>
  <reference>
    <citation>Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008 Jun;101(11):1388-95. doi: 10.1111/j.1464-410X.2008.07601.x.</citation>
    <PMID>18454794</PMID>
  </reference>
  <reference>
    <citation>Latini JM, Alipour M, Kreder KJ Jr. Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence. Urology. 2006 Mar;67(3):550-3; discussion 553-4.</citation>
    <PMID>16527577</PMID>
  </reference>
  <reference>
    <citation>Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE Jr, Scarpero HM, Tessier CD, Vasavada SP; American Urological Association; Society of Urodynamics, Female Pelvic Medicine &amp; Urogenital Reconstruction. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012 Dec;188(6 Suppl):2455-63. doi: 10.1016/j.juro.2012.09.079. Epub 2012 Oct 24.</citation>
    <PMID>23098785</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Andrea Staack</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

